Literature DB >> 8588666

Proliferation indices of vestibular schwannomas by Ki-67 and proliferating cell nuclear antigen.

W Szeremeta1, E M Monsell, J P Rock, D V Caccamo.   

Abstract

Two immunohistologic demonstrations of markers of proliferating cells, Ki-67 and proliferating cell nuclear antigen, were applied to tissues from 10 vestibular schwannomas. Each method demonstrated three distinct rates of positively stained cells (p < .01 and p < .015, respectively, for each method). There was a one-to-one correspondence between the two immunohistologic methods in the assignment of cases to each growth rate category except for two cases (Spearman rank correlation r = 0.76, p < .05). These data support the concept of distinct growth rates in vestibular schwannoma. Tissues were also sampled from different areas of the same tumor within nine samples. The results suggest that tumor growth is not homogeneous within a tumor, but that proliferation may be more active near the surface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8588666

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  3 in total

1.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

2.  Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma.

Authors:  Dustin M Dalgorf; Corwyn Rowsell; Juan M Bilbao; Joseph M Chen
Journal:  Skull Base       Date:  2008-11

3.  Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Pancras C W Hogendoorn; Inge Briaire-de Bruyn; Martijn J A Malessy; Andel G L van der Mey
Journal:  Virchows Arch       Date:  2012-05-04       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.